SCA
ADMS

Secor Capital Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

Secor Capital Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-10,369
Closed -$294K – 788
2015
Q4 		$294K Buy
+10,369
New +$175K 0.08% 382
2015
Q3 		– Sell
-9,729
Closed -$255K – 646
2015
Q2 		$255K Buy
+9,729
New +$189K 0.09% 330

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Secor Capital Advisors's ADMS Position: Q1 2016 in Review

Secor Capital Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q1 2016, closing a stake of 10,369 shares — an estimated $294K sold.

Secor Capital Advisors first reported a position in ADMS in Q2 2015 and held it in 2 quarters. The position peaked at $294K in Q4 2015. 84 funds tracked by Wall St. Rank hold ADMS as of Q1 2016.

  • Secor Capital Advisors reported no remaining Adamas Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Secor Capital Advisors sold 10,369 Adamas Pharmaceuticals shares in Q1 2016, an estimated $294K.
  • Secor Capital Advisors first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Secor Capital Advisors's Adamas Pharmaceuticals position peaked at $294K in Q4 2015.
  • 84 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2016.

Based on Secor Capital Advisors's 13F filing for Q1 2016, filed 10 May 2016.